Mike Donoviel

Mike Donoviel is Field Medical Director at Priovant Therapeutics. Mike brings more than 25 years of experience in medical affairs, drug discovery and development, and academic research. He left academia to join Lexicon Pharmaceuticals, where his team brought the company’s first immunomodulatory asset from target validation through Phase 2B clinical trials in RA. He has also held senior field-based medical affairs roles with Ikaria, Therakos, Mallinckrodt, and Arena supporting immunomodulatory therapies across a wide range of therapeutic areas, including autoimmunity, immuno-oncology, rheumatology, dermatology, and gastroenterology. Mike holds a BS in Biochemistry and Cellular Biology from the University of California, San Diego, and a Ph.D. in Molecular Genetics from the University of Washington, and completed a postdoctoral fellowship in Medical Genetics at the University of Toronto.